在这项研究中，该研究团队发现本质上是一种蛋白的朊病毒（prion）在GBM生物学中起着关键作用。 胶质母细胞瘤（GBM）是脑癌中最具侵袭性的类型之一，是医学面临的最大挑战之一，因为它很难治疗，死亡率高。在巴西，虽然没有确切的数字，但估计每年诊断出10000至12000例新病例。 GBM占所有脑瘤的近一半（49%），存活率极低，大多数患者在诊断后仅存活约12个月。因此，科学家们多年来一直在寻找新的治疗靶点，以开发更有效的治疗方法，提高这些患者的生存率和生活质量。 传统治疗包括手术切除肿瘤、化疗和放疗。主要使用的药物是替莫唑胺（temozolomide, TMZ），这是一种在20世纪90年代末获得批准的化疗药物，至今仍用于控制该疾病。问题是，尽管患者可能在几个月内没有肿瘤，但GBM很少对治疗有完全反应，几个月后会复发，通常以更具侵袭性和浸润性的形式复发。 考虑到这一点，巴西圣保罗大学生物医学科学研究所（ICB-USP）细胞与发育生物学系神经生物学与干细胞实验室的Marilene Hohmuth Lopes教授领导的一个研究团队决定更仔细地研究即使在完全治疗后仍留在脑组织中的GBM肿瘤细胞的

SAN FRANCISCO and SUZHOU, China, March 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the FRUSICA-2 Phase 2/3 clinical trial evaluating sintilimab in

EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With a high unmet need in these areas and limited competition, EMPAVELI's market is poised for steady growth. LAS VEGAS, March 18, 2025 /PRNewswire/ -- DelveInsight's " EMPAVELI Market Size, Forecast, and Market Insight Report" highlights the details around EMPAVELI, a complement inhibitor indicated to treat ad

Hepatic Artery Infusion therapy delivers treatment directly to metastatic tumors in the liver, while minimizing the potential for systemic side effects TAMPA, Fla., March 18, 2025 /PRNewswire/ -- AdventHealth Tampa is the first in the Tampa Bay area to offer a powerful new pump-based treatment option for colorectal cancer that has spread to the liver and for a rare form of cancer that forms in bile ducts within the liver called intrahepatic cholangiocarcinoma. Hepatic Artery Infusion (HAI) thera

Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in February 2025, with topline data expected in the second quarter of 2025 Announced positive outcome from sample size re-estimation in the Phase 2b CORAL

SELF-CERV study validates the Teal Wand at-home cervical cancer screening as a preferred and viable alternative to in-person screening. SAN FRANCISCO, March 18, 2025 /PRNewswire/ -- Teal Health, a women's health company on a mission to eradicate cervical cancer by bringing at-home cervical cancer screening to the US, announced groundbreaking clinical trial results at the Eurogin International Multidisciplinary HPV Conference, revealing that its Teal Wand™ self-collected cervical screening sampl

PITTSBURGH, March 18, 2025 /PRNewswire/ -- "The accessibility of dementia diagnostic imaging is limited in many low- and middle-income countries. There is an increased need in early dementia diagnosis to succeed in the development of preventative treatment approaches," said an inventor, from Caguas, Puerto Rico, "so I invented the FELICIANO INVENTION 1. My EEG design would focus on dementia diagnosis." The invention provides a modified medical device for brain imaging and interpreting different

Announced at the 2025 ACMG Annual Clinical Genetics Meeting in Los Angeles, CA BETHESDA, Md., March 18, 2025 /PRNewswire/ -- The American College of Medical Genetics and Genomics (ACMG) welcomed six new directors, including a new president-elect, to its Board of Directors at the 2025 ACMG Annual Clinical Genetics Meeting in Los Angeles, California. The new Board members will serve as advocates for the organization and will assist in shaping and implementing the mission, vision and direction of t

MARCY L'ÉTOILE, France, March 18, 2025 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration (FDA) 510(k) clearance for VITEK® COMPACT PRO. This innovative system for microorganism identification (ID) and antibiotic susceptibility testing (AST) will benefit clinical laboratories to help diagnose infectious diseases and combat antimicrobial resistance, and industrial laboratories to identify contaminants for ensuring cons

BETHESDA, Md., March 18, 2025 /PRNewswire/ -- The ACMG Foundation for Genetic and Genomic Medicine (ACMGF) announced today that James Lu, MD, PhD was elected to its board of directors. The ACMG Foundation is a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice. The board members are active participants, serving as advocates for the ACMG Foundation and for advancing its policies and programs. Dr. Lu was elected to a two-year term